News Releases

Feb. 8, 2001

Now on the Market : New Antipsychotic "Lullan® Tablets" - serotonin-dopamine antagonist originated in Japan -

Sumitomo Pharmaceuticals (President : Masaaki Yokotsuka) will market on Friday, February 9, a new antipsychotic, Lullan® Tablet 4 and Lullan® Tablet 8, as a prescription drug. The new product will be commercially promoted in cooperation with Yoshitomiyakuhin Corporation, which is a subsidiary of Welfide Corporation (President : Shinichiro Handa).

Lullan® Tablets (generic name: perospirone hydrochloride hydrate) is an atypical antipsychotic called a serotonin-dopamine antagonist (SDA). It alleviates both positive and negative symptoms of schizophrenia by antagonizing serotonin-2 and dopamine-2 receptors. Its additional merit is low incidence of extrapyramidal side effects.

For the treatment of schizophrenia, dopamine 2-receptor blockers have been generally used. Though they are effective in ameliorating the positive symptoms of the disease, they are poorly effective for the negative symptoms and frequently induce extrapyramidal side effects.

It has recently been shown that the serotonergic system are involved in the alleviation of negative symptoms and the suppression of extrapyramidal side effects. After intensive research to develop therapeutic drugs that can act on both dopaminergic and serotonergic nerves, Sumitomo Pharmaceuticals has hit upon "Lullan® Tablets," a SDA initially originated in Japan. It was officially approved as a prescription drug with the indication of schizophrenia on December 22, 2000, and registered in the official Drug Price List in February 2, 2001. Now the new product is ready to be marketed.

The "Lullan® Tablets" brand is manufactured and sold by Sumitomo Pharmaceuticals; its promotion is, however, carried out jointly by Sumitomo and Yoshitomiyakuhin. Sumitomo has long concentrated its R&D efforts on psycotherapeutis; Yoshitomiyakuhin, established last April as a corporation independent of Welfide on the basis of a part of its sales division dedicated to psychiatric field, has a powerful business base in the field. Both Sumitomo and Yoshitomiyakuhin hope to provide accurate information on this prescription drug to the medical and pharmaceutical professions as quickly as possible, so as to contribute to the betterment of schizophrenia treatment.

(1)  Binding affinity for serotonin and dopamine receptors (in vitro)
Lullan has a high binding affinity both for serotonin-2 and dopamine-2 receptors.
(2)  Antipsychotic actions by antagonizing serotonin-2 and dopamine-2 (in mice and rats)
Lullan acts as an antagonist for serotonin-2 and dopamine-2 receptors and ameliorates the behavioral abnormalities induced by the administration of various stimulants of dopaminergic and serotonergic systems.
(3)  Alleviation of positive and negative symptoms of schizophrenia
Positive symptoms of schizophrenia, including hallucination and delusion, as well as its negative symptoms, including emotional withdrawal and hypokinesia, were relieved.
(4)  Alleviation of neurotic symptoms in schizophrenia
Such neurotic symptoms as depression and anxiety were also alleviated.